Travis Wager

Dr. Wager is a leader in the pharmaceutical industry. In his 20 plus years of leadership experience driving drug discovery programs at Pfizer and Biotech Start-ups, Dr. Wager advanced eight small molecule drug candidates to clinical development. Included in the set of development candidates is the first kinase inhibitor (PF-05251749) for chronic CNS diseases. Biogen recently purchased this asset for $75 million upfront, with up to $635 million in milestone payments, as well as royalties. Dr. Wager is an internationally recognized expert in the field of brain-penetrant small molecule design. His seminal contributions to the understanding of CNS drug physicochemical properties and the development of the CNS MPO desirability tool has enabled both small and large neuroscience pharmaceutical groups to accelerate CNS drug discovery. In addition, he has published extensively and authored nearly 50 scientific papers, including two most cited papers, and is an inventor on over 35 patents and serves on the Scientific Advisory Board of ACS Chemical Neuroscience.